Deutsche Bank reviewed GSK's phase II data for its experimental mRNA flu vaccine, finding it closely resembles Moderna's candidate. Despite this, the bank views the results as only a minor positive since Moderna is further along in development. The disruptive potential of mRNA flu vaccines has diminished since the pandemic, and Deutsche Bank remains cautious about Moderna's launch prospects. GSK retains a strong position in the traditional flu vaccine market, providing some stability regardless of mRNA competition. The bank maintains a 'hold' rating on GSK with a target price of 2,000p, compared to the current share price of 1,859p.
Hutchmed secured a major licensing agreement with GSK worth $110 million upfront and up to $1.295 billion in milestone payments for its cancer drug HMPL-A830 outside Greater China. The deal highlights Hutchmed's strong oncology pipeline and led to a ...
Hutchmed's shares rose 17% after signing a licensing deal with GSK worth up to $1.295 billion for its experimental cancer drug HMPL-A830. GSK gains exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan, paying $110 million upfront plu...
Moderna's stock jumped 6% even as GSK moved its mRNA-based flu vaccine into Phase III trials, signaling strong confidence in mRNA technology beyond direct competition. GSK's vaccine showed promising immune responses in mid-stage trials and targets bo...
